Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04295694
Other study ID # 1997459
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 2014
Est. completion date June 21, 2017

Study information

Verified date March 2020
Source CAMC Health System
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Fever is a well-known side effect of immunizations. When a febrile infant presents to a healthcare site, such as an emergency room, a large number of tests are usually performed, which may include a procalcitonin (PCT) level. PCT is being increasingly recognized as an inflammatory marker suggestive of serious bacterial infection, and is being used in clinical practice in the workup for acute febrile illness. Based on an elevated PCT level, further testing may be done, antibiotics may be started, and the patient may get admitted to the hospital for observation before identifying the cause of the elevated PCT level. The investigators believe that immunizations can cause an increase in PCT levels in the absence of an acute infection. Thus, a finding of elevated procalcitonin in a recently immunized child may not have the same clinical implication as it does in other clinical scenarios. To investigate this, the investigators designed this pilot prospective study to compare PCT levels immediately before and forty-eight hours after the administration of routine infant immunizations. The investigators will enroll healthy infants presenting for their two, four, and six-month well child visits at FamilyCare - Children's Medicine Center and receiving routine immunizations as recommended by the Centers for Disease Control.


Description:

This pilot study is a prospective study enrolling infants who are currently healthy, have no acute illness in preceding fourteen days, and were born full term that are presenting at FamilyCare - Children's Medicine Center (CMC) for their 2, 4, and 6-month well child visit that includes routine immunizations. Following informed consent, a blood sample will be obtained from enrolled infants for PCT testing prior to their routine, scheduled immunizations. The infants will return to CMC to have their PCT levels re-tested at 2 days post immunization. An infant will be included in the study for only one well child visit; if an infant presents for a subsequent well child visit falling within our sample visit age, the infant is not eligible for study re-enrollment. The parent/guardian will be contacted via telephone at week post second blood draw to determine if the infant has experienced symptoms or received medical care during that time period. The patient population targeted for this pilot study will be infants presenting to their pediatricians at FamilyCare - Children's Medicine Center for two, four, or six-month well child visits on a Monday, Tuesday, or Wednesday and receiving their vaccines as recommended by the 2014 CDC schedule.10 This is a pilot study, and therefore had no power analysis performed to calculate sample size. The investigators anticipate that there will be a high rate of patients not returning for the second blood draw, approximately 50%, based on prior patient experience of the investigators. To achieve the sample of at least 20 patients completing both blood draws and the phone interview, the investigators will enroll 45 patients.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date June 21, 2017
Est. primary completion date July 1, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 8 Weeks to 28 Weeks
Eligibility Inclusion Criteria:

- • Infants receiving their 2,4, or 6 month well-child visit at FamilyCare-Children's Medicine Center that will include their normal, routine 2, 4, or 6 month immunizations (Prevnar®, Pediarix®, ActiHIB®, Rotateq®)

- Infant age 8 to 28 weeks old at time of study enrollment

- infant, with no acute illness (cough, congestion, fever, or decreased oral intake, …etc) in preceding fourteen days

- Infants born full term (37 weeks or more gestation)

Exclusion Criteria:

- • Infants born premature (born prior to 37th week of gestation)

- Having symptoms of illness in proceeding fourteen days (cough, congestion, fever, or decreased oral intake, …etc)

- Any previous hospitalizations, with exception of the hospitalization at birth

- Sick contacts in the home (contacts with symptoms of cough, congestion, or fever)

- Infants who received vaccines that are different from the standard vaccines that are administered in Children's Medicine Center, to maintain consistency of the study sample

- Infants with a chronic illness that increases their risk of infections (bronchopulmonary dysplasia, congenital heart disease, immunodeficiency…)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States FamilyCare HealthCenter Children's Medicine Center Charleston West Virginia

Sponsors (1)

Lead Sponsor Collaborator
CAMC Health System

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To compare change in PCT levels before and after routine immunization in healthy infants two to six months of age. a blood sample will be obtained from enrolled infants for PCT testing prior to their routine, scheduled immunizations. The infants will return to CMC to have their PCT levels re-tested at 2 days post immunization. 2 months up to 6 months
See also
  Status Clinical Trial Phase
Completed NCT02526394 - Pertussis and Meningitis C Concomitant Vaccination in Adolescents Phase 4
Completed NCT01707212 - Prenatal Education About Infant Immunization Pain Management Phase 3
Completed NCT01463176 - Music Therapy as Procedural Support for Young Children Undergoing Immunizations N/A
Completed NCT01193335 - Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants. Phase 4
Completed NCT04222595 - FluPRINT Study: Characterisation of the Immune and Transcriptional Response to LAIV N/A
Completed NCT05794113 - Comparing the Use of a Mobile App for Surveillance of Adverse Events Following Influenza Immunization to a Web-Based Platform N/A
Recruiting NCT01713322 - Testing Educational Materials in a Paediatric Setting Phase 3
Not yet recruiting NCT03705455 - Immunization Schedule Alert Platform N/A
Recruiting NCT01601197 - A Study of Two Injection Techniques to Reduce Pain in Infants Undergoing Immunization Phase 3
Completed NCT01296906 - Population Versus Practice-based Interventions to Increase Immunizations N/A
Completed NCT01399814 - Restricted Intravenous Fluid Regime Effects on Immunological Indicators of Elderly Patients Operated for Abdominal Cancer Phase 3
Completed NCT01390363 - Study of Adolescent Immunization Recall Systems N/A
Completed NCT02609035 - Immunization Services Model for Adult Rate Improvement N/A
Recruiting NCT02200276 - Influenza Immunization in Adults Over Age 75 N/A
Completed NCT01677702 - Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization N/A
Recruiting NCT05213000 - Adjuvant Effect of Physical Exercise on Immune Response to COVID-19 Vaccination and Interactions With Stress N/A
Completed NCT03188692 - Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants Phase 3
Completed NCT02432430 - Comparison of Immunization Quality Improvement Dissemination Study N/A
Completed NCT01379846 - Study of TAK-816 in Healthy Infants Phase 3
Active, not recruiting NCT03943875 - GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose Phase 4